Photodynamic Therapy Intraperitoneal Neoplastic Diseases

光动力治疗腹膜内肿瘤疾病

• 批准号: 6364691
• 负责人: ELI J. GLATSTEIN
• 金额: $ 161.43万
• 依托单位: UNIVERSITY OF PENNSYLVANIA
• 依托单位国家: 美国
• 财政年份: 2001
• 资助国家: 美国
• 起止时间: 2001-09-07 至 2005-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6364691
• 关键词: neoplasm /cancer photoradiation therapy; peritoneum neoplasm; photosensitizing agents

DESCRIPTION (provided by applicant) Patients with abdominal sarcomas, ovarian and gastrointestinal carcinomas have a major risk of peritoneal seeding (PS), for which results of conventional treatments are poor. We hypothesize that the combination of debulking surgery with intraperitoneal photodynamic therapy (IP PDT) will be an effective means of treating PS. IP PDT is adaptable to a wide and variable surface area, can kill multiple logs of cells and is acceptably safe to abdominal viscera. We propose to study the three major components of PDT (photosensitizer, oxygen and light), to optimize this treatment. In Project 1, we will continue our ongoing Phase II Photofrin-based clinical trial, for IP PDT in patients with recurrent PS. In addition Project 1 will investigate the efficacy and toxicity of second generation photosensitizers (SPG) in both rodent tumor systems and in large animal normal tissue models, respectively, with the aim of developing one of these compounds for future clinical trials of IP PDT. Project 2 will investigate the relationships of both tumor oxygenation and photosensitizer concentrations obtained from patient tissues to PDT response and to characteristics of tumor nodules (size, location and vascularity) by using fluorinated nitroimidazole (FN) drugs which bind and image areas of hypoxia. In Project 3, we will study both oxygen consumption and tumor vascularity during the PDT process 1 itself, by evaluating both Photofrin and other SGP in preclinical models that utilize these FN drugs in image 1: analysis studies. In Project 4, measurements of hemoglobin saturation by non-invasive techniques and quantification of light fluence will be determined directly during IP PDT. Also as part of Project 4, we will I characterize the optical properties of tissues within the peritoneum in terms of tissue scattering and absorption. Utilizing information from these investigations, we will use a SGP in a new Phase I study to optimize IP PDT as curative treatment strategy in patients with PS.

描述（由申请人提供） 患有腹部肉瘤，卵巢和胃肠道癌患者的患者患有 腹膜播种的主要风险（PS），为此结果 治疗很差。我们假设伪造手术的结合 腹膜内光动力疗法（IP PDT）将是一种有效手段 治疗PS。 IP PDT适用于宽且可变的表面积，可以 杀死多个细胞对数，并且对腹部内脏是安全的。我们 建议研究PDT的三个主要组成部分（光敏剂，氧气 和光），以优化这种处理。在项目1中，我们将继续我们的 IP PDT的基于II期光谱蛋白的临床试验正在进行中 复发性PS。另外，项目1将调查功效和 两种啮齿动物肿瘤中第二代光敏剂（SPG）的毒性 系统和大型动物正常组织模型的目标 开发其中一种用于IP的未来临床试验之一 太平洋夏令时。项目2将研究两种肿瘤氧合的关系 从患者组织到PDT获得的光敏剂浓度 对肿瘤结节特征的反应和特征（大小，位置和 血管性）通过使用结合和 缺氧的图像区域。在项目3中，我们将研究两种消耗 PDT过程1本身期间肿瘤血管性，通过评估两者 在临床前模型中使用这些FN药物的光蛋白和其他SGP 图像1：分析研究。在项目4中，血红蛋白的测量 通过非侵入技术和光通量定量的饱和度将 在IP PDT期间直接确定。作为项目4的一部分，我们将 我表征了腹膜内组织的光学特性 组织散射和吸收的术语。利用这些信息 调查，我们将在新的I阶段研究中使用SGP来优化IP PDT 作为PS患者的治疗治疗策略。